For instance, the ClinicalTrials.gov NCT02792465 study evaluated CFI-402257 as monotherapy and in combination with fulvestrant in a phase I trial in patients with advanced solid tumors, including HER2– breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.